Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like Judge Denies New Lawsuit for Parents Who Claimed Depakote Birth Defects November 27, 2017 Senators Seek Investigation Into Allergan’s Mohawk Tribe Patent Deal September 29, 2017 Fresenius Petitions FDA to Deny Second Indication for Keryx’s Chronic Kidney Disease Drug July 12, 2017
Fresenius Petitions FDA to Deny Second Indication for Keryx’s Chronic Kidney Disease Drug July 12, 2017